Related Experiment Video

Updated: Jul 16, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma

Christoph W M Reuter1, Michael A Morgan, Viktor Grünwald

  • 1Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Hannover, Germany. christophreuter@yahoo.com

World Journal of Urology
|March 7, 2007
PubMed

Insights

Metastatic renal cell carcinoma (RCC) shows poor response to traditional chemotherapy. Novel therapies targeting vascular endothelial growth factor (VEGF) signaling offer improved outcomes for patients with this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) is largely unresponsive to conventional chemotherapy.
  • Current immunotherapies offer limited remission rates (12.9% partial or complete remission).
  • There is a critical need for advanced therapies to improve survival and manage metastatic disease.

Purpose of the Study:

  • To review the efficacy of emerging molecularly targeted therapies for metastatic RCC.
  • To highlight treatments focusing on the vascular endothelial growth factor (VEGF) pathway.
  • To discuss recently approved agents representing new treatment standards.

Main Methods:

  • Review of scientific literature on targeted therapies for metastatic RCC.
  • Analysis of data on therapies targeting VEGF receptor (VEGFR) signaling.
  • Inclusion of recently FDA/EMEA-approved treatments.

Main Results:

  • Von Hippel-Lindau (VHL) gene inactivation in clear cell RCC leads to VEGF over-expression.
  • Targeted therapies, including anti-VEGF antibodies, VEGFR tyrosine kinase inhibitors, and mTOR inhibitors, show promise.
  • Several targeted agents have received regulatory approval, establishing new treatment paradigms.

Conclusions:

  • Targeting the VEGF pathway represents a significant advancement in metastatic RCC treatment.
  • Novel therapies offer improved efficacy over traditional approaches.
  • Approved VEGFR-targeted agents are becoming the standard of care for RCC patients.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: